Advantages of organ-sparing treatment approaches in metastatic kidney cancer-Reference-Cited by-同舟云学术

Advantages of organ-sparing treatment approaches in metastatic kidney cancer

Published:2022-07-23 Issue: Volume: Page:
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Vitruk Iurii^ORCID,Voylenko Oleg^ORCID,Stakhovsky Oleksandr^ORCID,Kononenko Oleksii^ORCID,Pikul Maksym^ORCID,Semko Sofiya^ORCID,Hrechko Bohdan^ORCID,Koshel Denis^ORCID,Stakhovsky Eduard^ORCID

Funder

National Health Care System of Ukraine

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-022-04216-6.pdf

Reference27 articles.

1. Abern MR, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ (2014) Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. Anticancer Res 34:2405–2411

2. Barbastefano J, Garcia JA, Elson P et al (2010) Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int 106:1266–1269. https://doi.org/10.1111/j.1464-410X.2010.09323.x

3. Barlow LJ, Korets R, Laudano M, Benson M, McKiernan J (2010) Predicting renal functional outcomes after surgery for renal cortical tumours: A multifactorial analysis. BJU Int 106:489–492. https://doi.org/10.1111/j.1464-410X.2009.09147.x

4. Bex A, Mulders P, Jewett M et al (2019) Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: The SURTIME randomized clinical trial. JAMA Oncol 5:164–170. https://doi.org/10.1001/jamaoncol.2018.5543

5. Bhindi B, Abel EJ, Albiges L et al (2019) Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol 75:111–128. https://doi.org/10.1016/j.eururo.2018.09.016

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and implementation of a prognostic model for clear cell renal cell carcinoma based on heterogeneous TLR4 expression;Heliyon;2024-02